Mycobacterium tuberculosis, the causative agent of tuberculosis (TB), is a successful intracellular pathogen that is responsible for the highest mortality rate among diseases caused by bacterial infections.
During early interaction with the host innate cells, M. tuberculosis cell surface antigens interact with Toll like receptor 4 (TLR4) to activate the nucleotide-binding domain, leucine-rich-repeat containing family, pyrin domain-containing 3 (NLRP3) canonical, and non-canonical inflammasome pathways.
NLRP3 inflammasome activation in the alveoli has been reported to contribute to the early inflammatory response that is needed for an effective anti-TB response through production of pro-inflammatory cytokines, including those of the Interleukin 1 (IL1) family.
However, overstimulation of the alveolar NLRP3 inflammasomes can induce excessive inflammation that is pathological to the host. Several studies have explored the use of medicinal plants and/or their active derivatives to inhibit excessive stimulation of the inflammasomes and its associated factors, thus reducing immunopathological response in the host.
This review describes the molecular mechanism of the NLRP3 inflammasome activation in the alveoli during M. tuberculosis infection.
Furthermore, the mechanisms of inflammasome inhibition using medicinal plant and their derivatives will also be explored, thus offering a novel perspective on the alternative control strategies of M. tuberculosis-induced immunopathology.
Exploring the Use of Medicinal Plants and Their Bioactive Derivatives as Alveolar NLRP3 Inflammasome Regulators during Mycobacterium tuberculosis Infection

Adjunct n-3 Long-Chain Polyunsaturated Fatty Acid Treatment in Tuberculosis Reduces Inflammation and Improves Anemia of Infection More in C3HeB/FeJ Mice With Low n-3 Fatty Acid Status Than Sufficient n-3 Fatty Acid Status

Populations at risk for tuberculosis (TB) may have a low n-3 polyunsaturated fatty acid (PUFA) status. Our research previously showed that post-infection supplementation of n-3 long-chain PUFA (LCPUFA) in TB without TB medication was beneficial in n-3 PUFA sufficient but not in low-status C3HeB/FeJ mice.
In this study, we investigated the effect of n-3 LCPUFA adjunct to TB medication in TB mice with a low compared to a sufficient n-3 PUFA status. Mice were conditioned on an n-3 PUFA-deficient (n-3FAD) or n-3 PUFA-sufficient (n-3FAS) diet for 6 weeks before TB infection.
Post-infection at 2 weeks, both groups were switched to an n-3 LCPUFA [eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA)] supplemented diet and euthanized at 4- and 14- days post-treatment. Iron and anemia status, bacterial loads, lung pathology, lung cytokines/chemokines, and lung lipid mediators were measured.
Following 14 days of treatment, hemoglobin (Hb) was higher in the n-3FAD than the untreated n-3FAS group (p = 0.022), whereas the n-3FAS (drug) treated control and n-3FAS groups were not.
Pro-inflammatory lung cytokines; interleukin-6 (IL-6) (p = 0.011), IL-1α (p = 0.039), MCP1 (p = 0.003), MIP1- α (p = 0.043), and RANTES (p = 0.034); were lower, and the anti-inflammatory cytokine IL-4 (p = 0.002) and growth factor GMCSF (p = 0.007) were higher in the n-3FAD compared with the n-3FAS mice after 14 days.
These results suggest that n-3 LCPUFA therapy in TB-infected mice, in combination with TB medication, may improve anemia of infection more in low n-3 fatty acid status than sufficient status mice.
Furthermore, the low n-3 fatty acid status TB mice supplemented with n-3 LCPUFA showed comparatively lower cytokine-mediated inflammation despite presenting with lower pro-resolving lipid mediators.

Exploring the Use of Medicinal Plants and Their Bioactive Derivatives as Alveolar NLRP3 Inflammasome Regulators during Mycobacterium tuberculosis InfectionChildhood Tuberculosis: An Under Prioritized Disease in Nepal

Globally, childhood tuberculosis constitutes up to 10% of overall tuberculosis cases. In Nepal, childhood tuberculosis has remained around 5.5% of overall tuberculosis cases and has remained stagnant over the years.
Moreover, our health system is focused on adult tuberculosis. Childhood tuberculosis has recently got its attention both at the national and international levels.
National Tuberculosis Program has been a successful program; however, more has to be done to track childhood tuberculosis progress. In this viewpoint, we discuss current initiatives taken by the government and the way forward for case detection and management of childhood tuberculosis in Nepal.

Analysis of the application of a gene chip method for detecting Mycobacterium tuberculosis drug resistance in clinical specimens: a retrospective study

Most Mycobacterium tuberculosis (Mtb) resistant to rifampicin (RIF) has mutations in the rpoB gene, while most Mtb resistant to isoniazid (INH) has mutations in the katG gene or inhA promoter.
We used gene chip technology to detect mutations in these genes to determine the resistance of Mtb to RIF and INH. A total of 4148 clinical specimens with sputum smear positivity for acid-fast bacilli (AFB) were detected.
Then, taking the results of the drug sensitivity test (DST) as the reference standard, the detection efficiency of sputum samples from different grades of positive smears was compared in detail.
Exploring the Use of Medicinal Plants and Their Bioactive Derivatives as Alveolar NLRP3 Inflammasome Regulators during Mycobacterium tuberculosis Infection
We found that the sensitivity of the gene chip method for detecting sputum samples with a grade ≥ AFB 2 + was higher than that of sputum samples with a grade ≤ AFB 1 + (P < 0.05).
When the grade of the sample was ≤ AFB 1 +, the sensitivity of the gene chip method was 72.6% for RIF, 67.3% for INH, and 60.0% for MDR-TB. When the grade of the sample was ≥ AFB 2 +, the sensitivity of the gene chip method was 84.5% for RIF, 78.2% for INH, and 73.9% for MDR-TB.
The results show that gene chip technology can be directly used to diagnose drug-resistant tuberculosis in clinical specimens, and the diagnostic efficiency for the detection of sputum specimens with a grade ≥ AFB 2 + is better than that of other sputum specimens.

Early phase of effective treatment induces distinct transcriptional changes in Mycobacterium tuberculosis expelled by pulmonary tuberculosis patients

Effective treatment reduces a tuberculosis patient’s ability to infect others even before they test negative in sputum or culture. Currently, the basis of reduced infectiousness of the Mycobacterium tuberculosis (Mtb) with effective treatment is unclear.
We evaluated changes in aerosolized bacteria expelled by patients through a transcriptomic approach before and after treatment initiation (up to 14 days) by RNA sequencing. A distinct change in the overall transcriptional profile was seen post-treatment initiation compared to pretreatment, only when patients received effective treatment.
This also led to the downregulation of genes associated with cellular activities, cell wall assembly, virulence factors indicating loss of pathogenicity, and a diminished ability to infect and survive in new host cells. Based on this, we identified genes whose expression levels changed with effective treatment.

Mycobacterium tuberculosis 16kD (M. tuberculosis)

MBS6009340-1mg 1(mg
EUR 885

Mycobacterium tuberculosis 16kD (M. tuberculosis)

MBS6009340-5x1mg 5x1mg
EUR 3830

Mycobacterium tuberculosis 16kD (M. tuberculosis)

MBS6011625-1mg 1(mg
EUR 1295

Mycobacterium tuberculosis 16kD (M. tuberculosis)

MBS6011625-5x1mg 5x1mg
EUR 5675

Mycobacterium tuberculosis (M. tuberculosis) Antibody

abx415707-1ml 1 ml
EUR 727.2

Mycobacterium tuberculosis (M. tuberculosis) Antibody

abx415707-200l 200 µl
EUR 537.5

Mycobacterium tuberculosis, HSP, Recombinant

MBS636978-01mg 0.1mg
EUR 735

Mycobacterium tuberculosis, HSP, Recombinant

MBS636978-5x01mg 5x0.1mg
EUR 3165

M. Tuberculosis HSP70 Protein

abx060544-100ug 100 ug
EUR 1378.8

Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE)

MBS6129466-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE)

MBS6129466-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE)

MBS6129467-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (PE)

MBS6129467-5x01mL 5x0.1mL
EUR 4775

Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP)

MBS6126370-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP)

MBS6126370-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP)

MBS6126371-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (AP)

MBS6126371-5x01mL 5x0.1mL
EUR 4775

Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP)

MBS6128846-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP)

MBS6128846-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP)

MBS6128847-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (HRP)

MBS6128847-5x01mL 5x0.1mL
EUR 4775

Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC)

MBS6126990-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC)

MBS6126990-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC)

MBS6126991-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (APC)

MBS6126991-5x01mL 5x0.1mL
EUR 4775

Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC)

MBS6128225-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC)

MBS6128225-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC)

MBS6128226-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (FITC)

MBS6128226-5x01mL 5x0.1mL
EUR 4775

Recombinant M. Tuberculosis HSP65

DAGA-194 0.1 mg Ask for price

Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin)

MBS6127611-01mL 0.1(mL
EUR 1240

Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin)

MBS6127611-5x01mL 5x0.1mL
EUR 5430

Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin)

MBS6127612-01mL 0.1(mL
EUR 1095

Mycobacterium tuberculosis 16kD (M. tuberculosis) (Biotin)

MBS6127612-5x01mL 5x0.1mL
EUR 4775

M. Tuberculosis LAM

DAGA-168 1 mg
EUR 1434

M. Tuberculosis MPT53

DAGA-171 100 µg
EUR 868.8

Recombinant Mycobacterium Tuberculosis HSP Protein

VAng-Yyj0063-10g 10 µg
EUR 2250
Description: Mycobacterium Tuberculosis, HSP, recombinant protein.

M. Tuberculosis 38 kDa

DAG-T2447 1 mg Ask for price

M. Tuberculosis 16 kDa

DAG-T2449 1 mg Ask for price

M. Tuberculosis 15.3 kDa

DAGA-169 1 mg
EUR 1170

MAb to M. tuberculosis

MBS310270-1mg 1mg
EUR 955

MAb to M. tuberculosis

MBS310270-5x1mg 5x1mg
EUR 4115

MAb to M. tuberculosis

MBS310271-1mg 1mg
EUR 1035

MAb to M. tuberculosis

MBS310271-5x1mg 5x1mg
EUR 4485

MAb to M. tuberculosis

MBS310272-1mg 1mg
EUR 1035

MAb to M. tuberculosis

MBS310272-5x1mg 5x1mg
EUR 4485

MAb to M. tuberculosis

MBS310273-1mg 1mg
EUR 1035

MAb to M. tuberculosis

MBS310273-5x1mg 5x1mg
EUR 4485

Mouse antibody for M. tuberculosis Hsp65

5177 100 ug
EUR 386.26
Description: This is purified Mouse monoclonal antibody against M tuberculosis Hsp65 for WB, ELISA.

Mouse antibody for M. tuberculosis Hsp65

5178 100 ug
EUR 386.26
Description: This is purified Mouse monoclonal antibody against M tuberculosis Hsp65 for WB, ELISA.

Rabbit A' M. tuberculosis

MBS315160-1mL 1mL
EUR 855

Rabbit A' M. tuberculosis

MBS315160-5x1mL 5x1mL
EUR 3685

Rabbit A' M. tuberculosis

MBS315161-1mL 1mL
EUR 915

Rabbit A' M. tuberculosis

MBS315161-5x1mL 5x1mL
EUR 3945

Rabbit A' M. tuberculosis

MBS315162-1mL 1mL
EUR 915

Rabbit A' M. tuberculosis

MBS315162-5x1mL 5x1mL
EUR 3945

Rabbit A' M. tuberculosis

MBS315163-1mL 1mL
EUR 800

Rabbit A' M. tuberculosis

MBS315163-5x1mL 5x1mL
EUR 3420

Monoclonal Anti-M. tuberculosis Heat Shock Protein 70 (hsp70/Dnak/ML2496) IgG

HSP701-M 100 ul
EUR 578.4

M. Tuberculosis TB22.2 Antigen

DAGA-186 100 µg
EUR 868.8

M. tuberculosis Moex protein

MBS596054-1mg 1mg
EUR 425

M. tuberculosis Moex protein

MBS596054-2mg 2mg
EUR 700

M. tuberculosis Moex protein

MBS596054-5mg 5mg
EUR 1505

M. tuberculosis CFP10, Recomb.

MBS319838-01mg 0.1mg
EUR 755

M. tuberculosis CFP10, Recomb.

MBS319838-5x01mg 5x0.1mg
EUR 3165

M. tuberculosis CFP10, Protein

abx061400-100ug 100 ug
EUR 961.2

M. tuberculosis ESAT6, Protein

abx061402-100ug 100 ug
EUR 910.8

M. Tuberculosis Mpt70 Antigen

DAGA-182 100 µg
EUR 868.8

M. Tuberculosis MPT83 Antigen

DAGA-183 100 µg
EUR 868.8

M. Tuberculosis Mpt64 Antigen

DAGA-184 100 µg
EUR 868.8

M. tuberculosis CFP10 Protein

abx061400-100g 100 µg Ask for price

M. tuberculosis CFP10 Protein

abx061400-10g 10 µg
EUR 1100

M. tuberculosis CFP10 Protein

abx061400-50g 50 µg Ask for price

M. Tuberculosis Rv2672 Antigen

DAGA-174 100 µg
EUR 868.8

M. Tuberculosis Rv2253 Antigen

DAGA-177 100 µg
EUR 868.8

M. Tuberculosis MT3413 Antigen

DAGA-178 100 µg
EUR 868.8

M. Tuberculosis Rv0477 Antigen

DAGA-179 100 µg
EUR 868.8

M. Tuberculosis Rv0192A Antigen

DAGA-173 100 µg
EUR 868.8

M. Tuberculosis Rv0398c Antigen

DAGA-176 100 µg
EUR 868.8

Mycobacterium tuberculosis 38 kDa Antigen (M. tuberculosis 38 kDa) Antibody

abx411025-02mg 0.2 mg
EUR 678

Mycobacterium tuberculosis 16 kDa Antigen (M. tuberculosis 16 kDa) Antibody

abx415759-01mg 0.1 mg
EUR 760.8

Mycobacterium tuberculosis 16 kDa Antigen (M. tuberculosis 16 kDa) Antibody

abx415759-200l 200 µl
EUR 600

Mycobacterium tuberculosis 38 kDa Antigen (M. tuberculosis 38 kDa) Antibody

abx411025-100g 100 µg
EUR 487.5

Mab to M. tuberculosis MPT64

MBS313702-1mg 1mg
EUR 515

Mab to M. tuberculosis MPT64

MBS313702-5x1mg 5x1mg
EUR 2135

Mab to M. tuberculosis MPT64

MBS313703-1mg 1mg
EUR 515

Mab to M. tuberculosis MPT64

MBS313703-5x1mg 5x1mg
EUR 2135

Mab to M. tuberculosis MPT64

MBS313704-1mg 1mg
EUR 515

Mab to M. tuberculosis MPT64

MBS313704-5x1mg 5x1mg
EUR 2135

Mab to M. tuberculosis MPT64

MBS313705-1mg 1mg
EUR 515

Mab to M. tuberculosis MPT64

MBS313705-5x1mg 5x1mg
EUR 2135

M. tuberculosis MPT64 Rec. Ag

MBS313721-1mg 1mg
EUR 515

M. tuberculosis MPT64 Rec. Ag

MBS313721-5x1mg 5x1mg
EUR 2155

M. tuberculosis MPT64 Rec. Ag

MBS313722-1mg 1mg
EUR 515

M. tuberculosis MPT64 Rec. Ag

MBS313722-5x1mg 5x1mg
EUR 2155

MAb to M. tuberculosis, 16kDa

MBS310461-1mg 1mg
EUR 605

MAb to M. tuberculosis, 16kDa

MBS310461-5x1mg 5x1mg
EUR 2640

MAb to M. tuberculosis, 38kDa

MBS310523-1mg 1mg
EUR 605

MAb to M. tuberculosis, 38kDa

MBS310523-5x1mg 5x1mg
EUR 2640

MAb to M. tuberculosis CFP10

MBS312553-1mg 1mg
EUR 805

MAb to M. tuberculosis CFP10

MBS312553-5x1mg 5x1mg
EUR 3455

MAb to M. tuberculosis CFP10

MBS312555-1mg 1mg
EUR 805

MAb to M. tuberculosis CFP10

MBS312555-5x1mg 5x1mg
EUR 3455

Recombinant M. tuberculosis 38kD

DAG-WT1091 1 mg
EUR 480
Description: Recombinant

M. tuberculosis, 38kDa, Recombinant

MBS319392-01mg 0.1mg
EUR 1150

M. tuberculosis, 38kDa, Recombinant

MBS319392-5x01mg 5x0.1mg
EUR 4995

M. Tuberculosis 38 kDa Protein

abx060636-100ug 100 ug
EUR 978

M. Tuberculosis 85-C Antigen

DAGA-175 100 µg
EUR 868.8

M. Tuberculosis 85-A Antigen

DAGA-181 100 µg
EUR 868.8

M. Tuberculosis 85-B Antigen

DAGA-185 100 µg
EUR 868.8

M. Tuberculosis 48 kDa protein

DAGA-191 1 mg Ask for price

M. Tuberculosis 38 kDa Protein

abx060636-100g 100 µg Ask for price

M. Tuberculosis 38 kDa Protein

abx060636-10g 10 µg
EUR 1437.5

M. Tuberculosis 38 kDa Protein

abx060636-50g 50 µg Ask for price

M. Tuberculosis 85A Antigen[his]

DAGA-189 10 µg
EUR 812.4

M. Tuberculosis 85A Antigen [His]

DAGA-192 50 µg
EUR 1228.8

M. Tuberculosis ESAT-6 Antigen

DAGA-187 100 µg
EUR 868.8

Native M. Tuberculosis LAM antigen

DAGC601 10 ug
EUR 978.6
Description: Native

Anti-Tb7.7 (M. tuberculosis) Purified

11-190-C100 0.1 mg
EUR 198

M. Tuberculosis Mpt63/MPB63 Antigen

DAGA-180 100 µg
EUR 868.8

Anti-Tb7.7 (M. tuberculosis) Purified

MBS1801449-01mg 0.1mg
EUR 305

Anti-Tb7.7 (M. tuberculosis) Purified

MBS1801449-5x01mg 5x0.1mg
EUR 1120

Anti-Acr1 (M. tuberculosis) Purified

11-185-C100 0.1 mg
EUR 198

Anti-Tb10.4 (M. tuberculosis) Purified

11-186-C100 0.1 mg
EUR 198

Anti-Tb10.3 (M. tuberculosis) Purified

11-187-C100 0.1 mg
EUR 198

Anti-Acr2 (M. tuberculosis) Purified

11-188-C100 0.1 mg
EUR 198

Anti-GlcB (M. tuberculosis) Purified

11-192-C100 0.1 mg
EUR 198

Recombinant M. Tuberculosis CFP-10

DAGA-170 1 mg
EUR 790.8

Anti-Acr1 (M. tuberculosis) Purified

MBS1801444-01mg 0.1mg
EUR 305

Anti-Acr1 (M. tuberculosis) Purified

MBS1801444-5x01mg 5x0.1mg
EUR 1120

Anti-Tb10.4 (M. tuberculosis) Purified

MBS1801445-01mg 0.1mg
EUR 305

Anti-Tb10.4 (M. tuberculosis) Purified

MBS1801445-5x01mg 5x0.1mg
EUR 1120

Anti-Tb10.3 (M. tuberculosis) Purified

MBS1801446-01mg 0.1mg
EUR 305

Anti-Tb10.3 (M. tuberculosis) Purified

MBS1801446-5x01mg 5x0.1mg
EUR 1120

Anti-Acr2 (M. tuberculosis) Purified

MBS1801447-01mg 0.1mg
EUR 305

Anti-Acr2 (M. tuberculosis) Purified

MBS1801447-5x01mg 5x0.1mg
EUR 1120

Anti-GlcB (M. tuberculosis) Purified

MBS1801450-01mg 0.1mg
EUR 305

Anti-GlcB (M. tuberculosis) Purified

MBS1801450-5x01mg 5x0.1mg
EUR 1120

Anti-Ag85b (M. tuberculosis) Purified

11-189-C100 0.1 mg
EUR 198

Anti-Ag85b (M. tuberculosis) Purified

MBS1801448-01mg 0.1mg
EUR 305

Anti-Ag85b (M. tuberculosis) Purified

MBS1801448-5x01mg 5x0.1mg
EUR 1120

M. Tuberculosis 63 kDa protein [His]

DAGA-190 1 mg Ask for price

Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70)

MBS638121-01mg 0.1mg
EUR 1135

Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70)

MBS638121-5x01mg 5x0.1mg
EUR 4960

Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70)

MBS637313-0002mg 0.002mg
EUR 375

Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70)

MBS637313-001mg 0.01mg
EUR 525

Heat Shock Protein 70, Recombinant, Mycobacterium tuberculosis (HSP70)

MBS637313-5x001mg 5x0.01mg
EUR 2210

Zmp1 M. tuberculosis Recombinant Protein

90-361 50 ug
EUR 752.1
Description: M13 endopeptidases are single-pass, transmembrane zinc-metallopeptidases responsible in human for the regulation of the biological activity of many hormones and peptides and are involved in many important processes such as blood pressure regulation (Neprilysin or NEP1), cardiovascular development (Endothelin Converting Enzyme-1 or ECE-12), prevention of haemolytic reaction (KELL) and phosphate homeostasis (PHEX). Zmp1 is a soluble enzyme member of the M13 endopeptidases family that plays a key role in Mycobacterium tuberculosis pathogenicity with a still unknown mechanism. Recently, it was shown to suppress inflammasome activation by inhibiting caspase-1 activation, thus preventing processing of pro-IL-1beta into IL-1beta and the consequent phagosome maturation.

Recombinant M. Tuberculosis Moex antigen

DAGA-213 1 mg Ask for price

OPMA04822-100UG - M. tuberculosis Protein

OPMA04822-100UG 0.1MG
EUR 849

M. Tuberculosis EsxB (LHP) (CFP10) Antigen

DAGA-188 100 µg
EUR 868.8

M. Tuberculosis ClpP Protease Assay Kit

TBP100K 100 assays
EUR 278.4
Description: This product includes 3100 ul of Assay Buffer and 310 ul of 10 x Substrate and 3500 ul of Stop solution. It is for 100 assays in 384-well plate format

Anti-CFP-10 (M. tuberculosis) Purified

11-490-C025 0.025 mg
EUR 99

Anti-CFP-10 (M. tuberculosis) Purified

11-490-C100 0.1 mg
EUR 198

Anti-ESAT-6 (M. tuberculosis) Purified

11-491-C025 0.025 mg
EUR 99

Anti-ESAT-6 (M. tuberculosis) Purified

11-491-C100 0.1 mg
EUR 198

Mouse antibody for M. tuberculosis 38kDa

5174 100 ug
EUR 386.26
Description: This is purified Mouse monoclonal antibody against M tuberculosis 38kDa for WB, ELISA.

Recombinant M. tuberculosis CFP10 (No tag)

DAG-WT1769 1 mg
EUR 1460
Description: Recombinant

Anti-CFP-10 (M. tuberculosis) Purified

MBS1801463-01mg 0.1mg
EUR 305

Anti-CFP-10 (M. tuberculosis) Purified

MBS1801463-5x01mg 5x0.1mg
EUR 1120

Anti-ESAT-6 (M. tuberculosis) Purified

MBS1801464-01mg 0.1mg
EUR 305

Anti-ESAT-6 (M. tuberculosis) Purified

MBS1801464-5x01mg 5x0.1mg
EUR 1120

Anti-Mycobacterium tuberculosis, heat shock protein 70 (HSP70) Antibody

Y059575 100 µg
EUR 325

Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (M. tuberculosis inhA) Antibody

20-abx109426
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Mycobacterium tuberculosis Enoyl-[acyl-carrier-protein] reductase [NADH] (M. tuberculosis inhA) Antibody

abx109426-100l 100 µl
EUR 162.5

M. tuberculosis 38 kDa recombinant antigen

8811 100 ug
EUR 477.6
Description: This is M. tuberculosis 38 kDa recombinant antigen for ELISA,WB.

Monoclonal antibody to M. tuberculosis CFP

MBS596232-1mg 1mg
EUR 480

Monoclonal antibody to M. tuberculosis CFP

MBS596232-2mg 2mg
EUR 700

Monoclonal antibody to M. tuberculosis CFP

MBS596232-5mg 5mg
EUR 1505

Recombinant purified M. tuberculosis Heat Shock Protein 70 (hsp70/hsp72/Dnak/ML2496) control for Western

HSP701-C 100 ul
EUR 343.2

OAMA02759-1ML - A' M. tuberculosis Antibody

OAMA02759-1ML 1ml
EUR 549

Mouse antibody for M. tuberculosis 16 kDa

5175 100 ug
EUR 386.26
Description: This is purified Mouse monoclonal antibody against M tuberculosis 16 kDa for WB, ELISA.

Mouse antibody for M. tuberculosis 16 kDa

5176 100 ug
EUR 386.26
Description: This is purified Mouse monoclonal antibody against M tuberculosis 16 kDa for WB, ELISA.

M. Tuberculosis p60-Related Protein Rv0024

DAGA-172 100 µg
EUR 868.8

Recombinant M. tuberculosis 38kD antigen [His]

DAG-WT1188 200 µg, 1 mg Ask for price
Description: Recombinant

M. Tuberculosis ESAT6-CFP10 fusion protein

MBS596212-1mg 1mg
EUR 425

M. Tuberculosis ESAT6-CFP10 fusion protein

MBS596212-2mg 2mg
EUR 700
The observations of the study open up avenues for further evaluating the changes in bacterial gene expression during the early phase of treatment as biomarkers for monitoring response to tuberculosis treatment regimens and provide means of identifying better correlates of Mtb transmission.

LEAVE A REPLY

Please enter your comment!
Please enter your name here